ShanXi C&Y Pharmaceutical Group Co.,LTD.

SZSE:300254 Stock Report

Market Cap: CN¥2.3b

ShanXi C&Y Pharmaceutical GroupLTD Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for ShanXi C&Y Pharmaceutical GroupLTD.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth18.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Improved Revenues Required Before ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) Shares Find Their Feet

Sep 30
Improved Revenues Required Before ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) Shares Find Their Feet

ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues

May 27
ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues

ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

Mar 25
ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Mar 06
ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ShanXi C&Y Pharmaceutical GroupLTD has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SZSE:300254 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024836831390N/A
6/30/2024835833198N/A
3/31/202480646580N/A
12/31/202379925438N/A
9/30/2023767-107624N/A
6/30/2023790-1201944N/A
3/31/2023820-1191336N/A
1/1/2023829-1194875N/A
9/30/2022847-1114182N/A
6/30/2022878-1104485N/A
3/31/2022899-9477114N/A
1/1/2022930-916097N/A
9/30/2021966-1443464N/A
6/30/2021911-1911346N/A
3/31/2021920-218-2612N/A
12/31/2020848-262-52-21N/A
9/30/2020861-162-327N/A
6/30/2020968-112-220N/A
3/31/20201,029-582642N/A
12/31/20191,13255170N/A
9/30/20191,184294145N/A
6/30/20191,154325267N/A
3/31/20191,119202443N/A
12/31/20181,1367938N/A
9/30/20181,09220-328N/A
6/30/20181,05818N/A35N/A
3/31/20181,02423N/A43N/A
12/31/201793922N/A40N/A
9/30/201789125N/A93N/A
6/30/201783431N/A64N/A
3/31/201779130N/A42N/A
12/31/201674630N/A42N/A
9/30/201673222N/A-15N/A
6/30/201670424N/A9N/A
3/31/201668322N/A32N/A
12/31/201568423N/A15N/A
9/30/201566940N/A43N/A
6/30/201566640N/A60N/A
3/31/201566041N/A56N/A
12/31/201465441N/A82N/A
9/30/201464638N/A80N/A
6/30/201459833N/A72N/A
3/31/201454729N/A76N/A
12/31/201351427N/A81N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 300254's forecast earnings growth is above the savings rate (2.8%).

Earnings vs Market: Insufficient data to determine if 300254's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 300254's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 300254's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 300254's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 300254's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y